Profile data is unavailable for this security.
About the company
Transcenta Holding Ltd is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
- Revenue in HKD (TTM)24.63m
- Net income in HKD-395.54m
- Incorporated2010
- Employees200.00
- LocationTranscenta Holding LtdB6-501, Biobay, 218 Xinghu StreetSUZHOU 215123ChinaCHN
- Websitehttps://www.transcenta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regent Pacific Group Ltd | 1.99m | -120.59m | 91.38m | 17.00 | -- | -- | -- | 45.97 | -0.5279 | -0.5279 | 0.0087 | -0.139 | 0.0288 | -- | 11.86 | 116,919.00 | -174.72 | -50.00 | -279.01 | -59.04 | -- | -- | -6,067.06 | -2,685.21 | -- | -152.22 | -- | -- | 574.47 | -44.72 | 31.24 | -- | -50.60 | -- |
| Canbridge Pharmaceuticals Inc | 115.38m | -449.91m | 125.33m | 93.00 | -- | -- | -- | 1.09 | -1.06 | -1.06 | 0.2717 | -0.728 | 0.2558 | 2.32 | 3.81 | 1,153,766.00 | -99.74 | -- | -1,160.07 | -- | 63.97 | -- | -389.95 | -- | 0.2146 | -44.04 | -- | -- | 30.26 | -- | 21.64 | -- | -- | -- |
| Kontafarma China Holdings Ltd | 836.92m | -63.24m | 173.25m | 717.00 | -- | 0.1628 | 16.90 | 0.207 | -0.0113 | -0.0113 | 0.150 | 0.1904 | 0.4756 | 3.52 | 6.67 | 1,162,388.00 | -4.95 | -1.33 | -6.40 | -2.18 | 59.88 | 54.70 | -10.40 | -4.12 | 1.24 | -6.56 | 0.2116 | -- | -9.50 | -17.32 | 66.02 | -- | -19.55 | -- |
| Modern Chinese Medicine Group Co Ltd | 265.36m | 15.84m | 189.00m | 190.00 | 11.93 | 0.3673 | 8.30 | 0.7122 | 0.0264 | 0.0264 | 0.4423 | 0.8577 | 0.482 | 5.62 | 4.24 | 1,389,328.00 | 2.88 | 20.76 | 3.08 | 25.82 | 27.70 | 41.02 | 5.97 | 20.11 | 10.90 | -- | 0.001 | 2.54 | -13.91 | 14.67 | -44.44 | 0.2303 | 96.96 | -- |
| Wai Yuen Tong Medicine Holdings Limited | 783.88m | -26.68m | 219.40m | 810.00 | -- | 0.1647 | 2.68 | 0.2799 | -0.0228 | -0.0132 | 0.6636 | 1.18 | 0.1721 | 0.4001 | 10.55 | 967,754.30 | -0.1597 | -0.3053 | -0.2538 | -0.5206 | 50.37 | 43.82 | -0.928 | -2.18 | 1.37 | 2.13 | 0.2879 | -- | 8.33 | 0.8488 | -62.16 | -- | 15.35 | -- |
| Shenzhen Neptunus Intrlng Bi tchnq CoLtd | 1.16bn | 35.46m | 244.99m | 1.47k | 6.91 | 0.2348 | 667.07 | 0.2108 | 0.0211 | 0.0211 | 0.6926 | 0.6218 | 0.7383 | 3.11 | 3.99 | 804,883.50 | 1.73 | 3.46 | 2.56 | 5.13 | 37.47 | 49.14 | 2.34 | 4.29 | 2.20 | 29.81 | 0.082 | 0.00 | 7.92 | 4.19 | -55.60 | -12.89 | -11.10 | -- |
| PuraPharm Corp Ltd | 419.41m | -87.09m | 265.25m | 525.00 | -- | 2.03 | -- | 0.6325 | -0.2205 | -0.2205 | 1.06 | 0.3296 | 0.4854 | 1.15 | 5.92 | 633,542.30 | -10.08 | -9.20 | -30.69 | -19.70 | 51.97 | 59.52 | -20.77 | -19.33 | 0.3116 | -1.36 | 0.7597 | -- | -9.20 | -11.41 | 11.76 | -- | -13.68 | -- |
| Hin Sang Group (Interntnl) Hldng Co Ltd | 92.62m | -36.71m | 316.62m | 247.00 | -- | 1.52 | -- | 3.42 | -0.0336 | -0.0336 | 0.0848 | 0.1913 | 0.1536 | 2.34 | 10.34 | 374,967.60 | -6.04 | -5.11 | -9.78 | -7.04 | 61.98 | 59.72 | -39.30 | -28.42 | 0.1287 | -1.68 | 0.6054 | -- | 13.70 | -12.83 | 25.84 | -- | -69.21 | -- |
| Transcenta Holding Ltd | 24.63m | -395.54m | 452.80m | 200.00 | -- | 0.4229 | -- | 18.39 | -0.974 | -0.974 | 0.0607 | 2.46 | 0.0131 | 0.8106 | 0.5768 | 114,540.40 | -21.08 | -- | -29.77 | -- | 26.02 | -- | -1,606.19 | -- | 1.04 | -31.65 | 0.2826 | -- | -47.15 | -- | -13.72 | -- | -- | -- |
| Uni-Bio Science Group Ltd | 508.40m | 98.86m | 474.60m | 458.00 | 4.85 | 1.50 | 3.99 | 0.9335 | 0.0159 | 0.0159 | 0.0812 | 0.0514 | 1.27 | 2.23 | 9.05 | 1,249,140.00 | 24.76 | 1.46 | 32.97 | 1.97 | 83.51 | 80.59 | 19.44 | 1.23 | 2.17 | 168.55 | 0.2267 | 0.00 | 10.08 | 29.08 | 84.04 | -- | 84.98 | -- |
| Tianda Pharmaceuticals Ltd | 384.68m | -47.26m | 509.56m | 695.00 | -- | 0.9358 | -- | 1.32 | -0.022 | -0.022 | 0.1789 | 0.2533 | 0.4341 | 2.97 | 4.46 | 445,745.10 | -5.34 | -- | -7.97 | -- | 45.83 | -- | -12.30 | -- | 0.6748 | -9.51 | 0.1536 | -- | -- | -- | -- | -- | -- | -- |
| 3D Medicines Inc | 539.11m | -495.99m | 557.73m | 198.00 | -- | 0.5964 | -- | 1.03 | -2.11 | -2.11 | 2.26 | 3.62 | 0.3746 | 4.94 | 5.79 | 2,722,764.00 | -37.27 | -- | -50.88 | -- | 91.97 | -- | -99.50 | -- | 2.56 | -- | 0.2517 | -- | 11.91 | -- | 48.78 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Transcenta Holding Ltd's reporting currency: Hong Kong Dollar HKD
5.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullerton Fund Management Co. Ltd.as of 31 Dec 2023 | 26.02m | 5.96% |
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
